Background: Venous thromboembolism (VTE) is a complication of COVID-19 in hospitalized patients. Little information is available on long-term outcomes of VTE in this population. Objectives: We aimed to compare the characteristics, management strategies, and long-term clinical outcomes between patients with COVID-19–associated VTE and patients with VTE provoked by hospitalization for other acute medical illnesses. Methods: This is an observational cohort study, with a prospective cohort of 278 patients with COVID-19–associated VTE enrolled between 2020 and 2021 and a comparison cohort of 300 patients without COVID-19 enrolled in the ongoing START2-Register between 2018 and 2020. Exclusion criteria included age <18 years, other indications to anticoagulant treatment, active cancer, recent (<3 months) major surgery, trauma, pregnancy, and participation in interventional studies. All patients were followed up for a minimum of 12 months after treatment discontinuation. Primary end point was the occurrence of venous and arterial thrombotic events. Results: Patients with VTE secondary to COVID-19 had more frequent pulmonary embolism without deep vein thrombosis than controls (83.1% vs 46.2%, P <.001), lower prevalence of chronic inflammatory disease (1.4% and 16.3%, P <.001), and history of VTE (5.0% and 19.0%, P <.001). The median duration of anticoagulant treatment (194 and 225 days, P = 0.9) and the proportion of patients who discontinued anticoagulation (78.0% and 75.0%, P = 0.4) were similar between the 2 groups. Thrombotic event rates after discontinuation were 1.5 and 2.6 per 100 patient-years, respectively (P = 0.4). Conclusion: The risk of recurrent thrombotic events in patients with COVID-19–associated VTE is low and similar to the risk observed in patients with VTE secondary to hospitalization for other medical diseases.
Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes / Ageno, W.; Antonucci, E.; Poli, D.; Bucherini, E.; Chistolini, A.; Fregoni, V.; Lerede, T.; Pancani, R.; Pedrini, S.; Pieralli, F.; Pignatelli, P.; Pizzini, A. M.; Podda, G. M.; Potere, N.; Sarti, L.; Testa, S.; Visona, A.; Palareti, G.; Girardi, L.; Sterpone, P.; Cosmi, B.; Serrao, A.; Di Nisio, M.; Porreca, E.; Grandone, E.; Colaizzo, D.; Insana, A.; Falanga, A.; Martinelli, I.; Bucciarelli, P.; Abbattista, M.; Martini, G.; Masciocco, L.; Mastroiacovo, D.; Carrozzi, L.; Paparo, C.; Milia, A.; Menichelli, D.; Silingardi, M.; Birocchi, S.; Crudele, F.; Lotti, E.; Marcucci, R.; Preti, P. S.; Trovati, A.; Caronna, A.; Famiglietti, E.; Lami, F.; Nicolini, A.; Scaglioni, F.; Paoletti, O.; Tosetto, A.; Toma, A.; Villalta, S.; Zalunardo, B.; Panzavolta, C.. - In: RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS. - ISSN 2475-0379. - 7:4(2023), p. 100167. [10.1016/j.rpth.2023.100167]
Venous thromboembolism secondary to hospitalization for COVID-19: patient management and long-term outcomes
Chistolini A.;Pignatelli P.;Bucciarelli P.;Abbattista M.;Menichelli D.;
2023
Abstract
Background: Venous thromboembolism (VTE) is a complication of COVID-19 in hospitalized patients. Little information is available on long-term outcomes of VTE in this population. Objectives: We aimed to compare the characteristics, management strategies, and long-term clinical outcomes between patients with COVID-19–associated VTE and patients with VTE provoked by hospitalization for other acute medical illnesses. Methods: This is an observational cohort study, with a prospective cohort of 278 patients with COVID-19–associated VTE enrolled between 2020 and 2021 and a comparison cohort of 300 patients without COVID-19 enrolled in the ongoing START2-Register between 2018 and 2020. Exclusion criteria included age <18 years, other indications to anticoagulant treatment, active cancer, recent (<3 months) major surgery, trauma, pregnancy, and participation in interventional studies. All patients were followed up for a minimum of 12 months after treatment discontinuation. Primary end point was the occurrence of venous and arterial thrombotic events. Results: Patients with VTE secondary to COVID-19 had more frequent pulmonary embolism without deep vein thrombosis than controls (83.1% vs 46.2%, P <.001), lower prevalence of chronic inflammatory disease (1.4% and 16.3%, P <.001), and history of VTE (5.0% and 19.0%, P <.001). The median duration of anticoagulant treatment (194 and 225 days, P = 0.9) and the proportion of patients who discontinued anticoagulation (78.0% and 75.0%, P = 0.4) were similar between the 2 groups. Thrombotic event rates after discontinuation were 1.5 and 2.6 per 100 patient-years, respectively (P = 0.4). Conclusion: The risk of recurrent thrombotic events in patients with COVID-19–associated VTE is low and similar to the risk observed in patients with VTE secondary to hospitalization for other medical diseases.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
